<DOC>
	<DOCNO>NCT01048307</DOCNO>
	<brief_summary>Objective : To evaluate efficacy safety Prontosan® Wound Irrigation Solution treatment hard-to-heal venous leg ulcer compare wound irrigation saline solution Methodology : Randomised , control multi-centre , prospective clinical trial Planned number subject : 20 patient experimental group ( Prontosan® Wound Irrigation Solution ) 8 patient control group ( wound irrigation saline ) Products investigation : Prontosan® Wound Irrigation Solution Study Duration : 3-4 week</brief_summary>
	<brief_title>Effect Prontosan Wound Irrigation Solution Venous Ulcers</brief_title>
	<detailed_description>Investigational product , dose administration : Prontosan® Wound Irrigation Solution ( experimental group ) saline solution ( control group ) apply inclusion reapplied dressing change . The treatment scheme follow : 1 . Prontosan® Wound Irrigation Solution ( experimental group ) : - cleanse wound bed dress change Prontosan® Wound Irrigation Solution ; sterile gauze dress impregnated Prontosan® solution place immediate wound form moist compress remove approximately 15 minute ; - placing primary dressing ( Profore® WCL ) : dressing impregnate Prontosan® Wound Irrigation Solution ; - fix dress wound use multilayered elastic compression bandaging ( Profore® bandage system ) . 2 . Saline ( control group ) : - cleanse wound bed dress change saline ; sterile gauze dress impregnated saline place wound form moist compress remove approx.15 minute ; - placing primary dressing ( Profore® WCL ) : dressing impregnated saline ; - fix dress wound use multilayered elastic compression bandaging ( Profore® bandage system ) . Dressings change treatment procedure repeat clinic 2x/weekly . The efficacy treatment procedure evaluate basis 2 week observation period . Treatment efficacy assessment : - Assessment clinical sign symptom entry study one two week . - Quantitative qualitative microbiological analysis entry study two week . - Wound planimetry use PictZar® CDM entry study two week . Primary aim : - clinical sign assess : 1. reduction slough necrotic tissue 2. control exudate 3. presence granulation tissue - reduction inflammatory sign ( surround skin ) - reduction wound size ( assess wound planimetry ) - reduction bacterial load ( quantitative qualitative microbiological Secondary aim : - tolerance safety assessment : 1. adverse drug reaction 2. adverse event 3. early withdrawal study</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Betaine</mesh_term>
	<criteria>male female age least 18 wound venous aetiology ( document target exam ) locate low limb Ankle Brachial Index ( ABI ) ≥ 0.7 patient antimicrobial ( systemic antibiotic topical antiseptic ) 30 day join study Exclusion criterion age 18 year presence clinical infection , current use antiseptic antibiotic chronic wound long duration ( &gt; 30cm2 &gt; 1 year duration ) involvement wound related trial within past 30 day sensitivity component Prontosan® dress material intolerance compression therapy active osteomyelitis ulceration area active rheumatoid arthritis ( RA ) require immunosuppressive therapy collagen vascular disease active treated steroid chronic disease could impact course study ( malicious cancer , TB , AIDS , mental illness ) plasma protein 4 g/dl anaemia : haemoglobin 10 g/dl , control uncontrolled diabetic ( type 1 2 ) patient rheological agent ( include aspirin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>prontosan</keyword>
	<keyword>wound cleansing</keyword>
	<keyword>wound irrigation</keyword>
	<keyword>phmb</keyword>
	<keyword>polihexanide</keyword>
	<keyword>betaine</keyword>
</DOC>